Abstract The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovered 20 publications and matched them to Affymetrix HGU133A annotations. Raw Affymetrix HGU133A microarray data were extracted from GEO and MAS5 normalized. For classifying patients using the selected gene sets, we applied prediction analysis of microarrays and constructed KaplanMeier plots. A new classification including all patients was generated using supervised principal components analysis. Seven studies including 1,470 patients were downloaded from GEO. Notably, we uncovered 641 microarrays representing 251 individual tumor specimens among them, which were repeatedly described under independent GEO identifiers. We excluded all redundant data and used the remaining 1,079 samples. Eight of the 20 gene sets were able to predict response at a significance of P \ 0.05. The discrimination of good and poor prognosis groups exclusively relying on gene expression data resulted in high significance (P = 1.8E-12). A model including genes fitted by both gene expression and clinical covariates (lymph node status and grade) contains 44 genes and can predict response at P = 9.5E-7. The outcome provides a ranking of the gene lists regarding applicability on an independent dataset. We established a consensus predictor combining the available clinical and gene expression data. The database comprising expression profiles of 1,079 breast cancers can be used to classify individual patients.
Introduction
Although molecular markers like expression of estrogen and growth factor receptors, pS2, metallothionein, CD24, cathepsin D, ERBB2, and mutations in the TP53 gene all have been correlated to breast cancer prognosis, the use of single marker provides limited information for the prognosis of an individual patient [1, 2] . In view of the molecular heterogeneity of breast tumors and the large number of marker genes involved, studying multiple genetic alterations simultaneously is of utmost importance. With the arrival of microarray technologies, searches for tumor markers can be performed in a discovery-driven manner in high through-put.
The first microarray-based breast cancer studies have revealed distinct clinical phenotypes. Two major types, basal and luminal, have been identified, each with the potential to be subdivided into additional subtypes [2] [3] [4] [5] . Although histological grade can provide clinically important prognostic information, as many as 30-60% of tumors are classified as grade 2. This grade is associated with an intermediate risk of recurrence and is thus not informative for clinical decision making. Gene expression signatures capable of discerning tumors of grade 1 (G1) and grade 3 (G3) histology might provide a more objective measure of grade with prognostic benefit for patients with G2 disease [5] .
Estrogen receptor (ER) status is the only globally accepted treatment predictive factor for hormonal therapy in primary breast cancer. As only a small proportion (7%) of cells in the normal mammary epithelium express ER [6] , receptor status is the main discriminator in the high proportion of ER? tumors. The ER status of breast tumors has been suggested to either reflect tumor progression with ER-tumors evolving from ER? precursors, or to indicate a distinct origin from different types of epithelial cells in the mammary gland. Metastases from ER? tumors may be ER- [7] supporting the hypothesis that ER-expressing and ER-negative breast cancers represent different disease entities [8] . In contrast, a large proportion of the patients with ER? breast cancer do not respond to tamoxifen. These unsolved issues led to a significant number of studies investigating ER status and prognosis in breast cancer [8] [9] [10] [11] [12] .
While many of these studies presented promising results, most proposed markers were not reproduced in consecutive studies. The proposed best discriminatory genes rarely match in different studies. A major criticism has been that in 90% of early reports the validation set of patients overlaps with the training set [13] . Additional critical issues regarding the use of microarray data for prognostic classification include gene selection bias, error estimation, fragility of gene signatures, and overoptimistic performance estimation due to model over-fitting [14] . Over-fitting means finding a discriminatory gene pattern by chance. This can happen when large numbers of variables (genes) are assessed for a small number of samples [13] .
Michiels et al. re-analyzed data from seven large published studies that have attempted to predict prognosis of cancer patients using data from DNA microarray analysis. They expanded the standard strategy based on unique training and validation sets by using multiple random sets. The list of genes identified as predictors of prognosis was highly unstable; molecular signatures strongly depended on the selection of patients in the training sets, the proportion of misclassified patients decreased as the number of patients in the training set increased. Five of the seven studies did not classify patients better than chance [15] .
Thus, information based on microarray analysis requires independent validation in distinct data sets [16] . While the use of microarray technology as a diagnostic tool can potentially revolutionize current breast cancer management, critical scientists advocate further studies with profiling of larger cohorts using single microarray platforms before prospective clinical use of molecular classifiers can be contemplated [17] .
In present study we aimed to perform a large-scale meta-analysis to compare several different gene sets for predicting relapse in a set of raw microarray data accessible through Gene expression omnibus (GEO). A second aim of the study was to establish a consensus predictor combining all suggested genes and available patient samples.
Methods

Included raw microarray studies
We systematically searched GEO (http://www.ncbi.nlm. nih.gov/geo/) using the keywords ''breast cancer'' and ''gpl96'' (platform accession for Affymetrix HGU133A microarrays). Only studies publishing data for more than 20 patients with available clinical information were considered. Seven studies published such raw data in GEO, which were downloaded.
Included gene lists
We have searched Pubmed using the keywords ''breast cancer'' and ''microarray''. The search was then limited to studies in English with Pubmed accessible text. Only genome-wide association studies were selected. Studies investigating \20 patients or publishing \5 genes were excluded from the study.
Annotation and matching to the Affymetrix IDs was performed using the Affymetrix Netaffx analysis centre (http://www.affymetrix.com/analysis/index.affx). For the construction of the matched gene lists the available gene identifiers (Unigene ID, Genbank Accession, gene symbol, Affymetrix ID) were used. The datasets were combined using Microsoft Access 2007.
Statistical analyses
The downloaded data was MAS 5.0 normalized in the R statistical environment (http://www.R-project.org). MAS5.0 applies normalization on an individual chip; it has excellent specificity and good sensitivity. As MAS 5.0 it is the factorydefault normalization method, in the future even single microarrays can be added to our table.
In order to apply the gene sets we used the updated version of the ''Prediction Analysis for Microarrays'' (PAM) [18] which uses a semi-supervised method to predict patient survival [19] . PAM was performed in a leave-one-out cross validation and the threshold was set to include all genes in the prediction. When investigating datasets with GEO available microarrays, the original dataset was excluded from the analysis. PAM is a modification of the nearest-centroid method and was applied as previously described.
For establishing a new, consensus predictor, the BRB Arraytools 3.6.0-beta_3 package was used (developed by Dr. Richard Simon and Amy Peng Lam, available at http://linus.nci.nih.gov/BRB-ArrayTools.html). Instead of using a separate test-set and training-set we performed a leave-one-out cross validation to assess the performance of the new predictor. When investigating the gene sets of the seven studies delivering the GEO data, the samples resulting from the corresponding study were excluded from the analysis to avoid inclusion of the training set (the original samples the gene list was derived from) in the test set. An overview of the applied analytical pathway is depicted on Fig. 1 .
Using a new approach implemented in BRBArrayTools we evaluated whether the expression data provides more accurate predictions than that provided by the two other significant clinical covariates, lymph-node status and grade. Here, an additional model is developed for a combination of the covariates and the expression data. For each cross-validated training set, genes are selected which add to predicting survival over the predictive value provided by the covariates. The principal components of those genes are computed and a model fitted containing the covariates and the supervised principal components. The survival risk group for the patient omitted from that training set is predicted using that composite model. Finally a P value is determined which measures whether the expression data adds significantly to risk prediction compared to the covariates.
Descriptive statistics, significance for clinical variables and survival plots were constructed using the Winstat for Excel software.
Results
Creating a non-redundant database for breast cancer specimens subjected to expression profiling Altogether, GEO listed 1,470 raw GPL96 microarray samples from published studies. When surveying the clinical data, we observed a high similarity between some studies. Therefore, we compared the gene expression data of all microarrays and identified 641 redundant samples related to 251 individual raw microarray files first published in GEO under the series accession number GSE3494. The remaining datasets (GSE2990, GSE4922 and GSE6532) include 389 microarrays identical to GSE3494 but supplemented with additional clinical information (some microarrays were deposited more than twice). We have listed the redundant GSE3494 samples in Supplemental Table 1 for future reference. The database includes the GEO series accession numbers, the GEO sample accession numbers and the average of normalized expression values of all transcripts for a given sample. We found identical average expression values only on identical microarrays. As none of the publications showed the complete clinical information, we merged the individual clinical features into one database ( Table 1 ). The complete dataset containing the normalized expression values of the 1,079 chips is shown in Supplemental Table 2 . The Supplemental Table 3 containing the detailed clinical information records includes all available clinical data for each patient. We excluded all redundant samples for the statistical analysis totaling 1,079 microarrays.
Meta-analysis of published gene sets
Twenty-four published studies representing 20 gene sets with discriminatory potential for clinical relapse were included in the study. If several gene lists were available in these studies, we selected the most extensive one exhibiting statistical significance. The gene lists are summarized in Table 2 .
For the meta-analysis of the previously published breast cancer associated genes we used Prediction Analysis of Microarrays to predict the risk of relapse using the nonredundant set of microarrays. The analysis was performed independently for all 20 published discriminatory gene GEO raw datasets, n=7 (Table 1) Gene sets, n=20 Normalization: MAS5 (Table 2 Kaplan-Meier plots (Figure 2 ) Fig. 1 Overview of the applied analytical pathway (Table 2) . Using PAM we also constructed the training error plots to estimate the performance of top discriminatory genes defined in these studies. Notably, even gene sets exhibiting low overall predictive ability contained some top genes capable of discriminating patient tumors with or without relapse (data not shown).
Establishing a new predictor for relapse-free survival
We have computed a new predictor based on all genes associated with breast cancer and all available microarrays. In this setting only the gene expression data was used. In the supervised principal component analysis the threshold was set to 0.001 to fit Cox proportional hazard model. The best discriminatory gene signature contains 376 genes (Supplemental Table 4 ) and the result of a leave-one-out discrimination has a significance of 1.8E-12. The KaplanMeier survival plot is presented in Fig. 2 . We have calculated the predictive power of the available clinical variables: lymph node status (P = 0.01) and grade (P = 0.0005) were significant, while ER status (P = 0.11) was not predictive for relapse-free survival (Fig. 2) . Therefore, the predictive calculation was extended to evaluate whether the expression data provides more accurate predictions than that provided by the two other significant clinical covariates, lymph-node status and grade. Forty-four genes performed over the adjusted clinical covariates. The prediction based on these genes and the clinical covariates was highly significant (P = 9.5E-7) and is presented in Fig. 2 and the gene list in Supplemental Table 3 .
Establishing a database for future predictions All available MAS 5.0 normalized microarray expression data were merged into a large training set to permit inclusion of new patient data as test samples and to allow classification of those in a straight forward manner. The complete data set of all samples with complete clinical information (and the necessary experiment descriptor file) is available as Supplemental Tables 5 and 6 in a BRBArrayTools compatible format for independent application.
Discussion
We have critically assessed the potential of microarray data for predicting relapse-free survival in breast cancer patients based on a large cohort of tumor samples (n = 1,079) previously collected in and documented by different clinical centers. The gene lists which were developed to predict prognosis generally outperform those [27] Only MAS5 data. Used complex analysis including different techniques. Validated in [29] and [37] 76 transcripts 0.00001 (gse2034 excluded)
180
As of [27] Validation of predictor [37] --
198
As of [27] Validation of predictor [29] Unavailable online software used for analysis --651
As of [9] Prediction of chemotherapy benefit [38] Used Cox proportional hazards model The analysis results correspond to the P value of a Kaplan-Meier after classification of patients described in Table 1 with PAM using the matched set of genes published
The values in bold denote significance at P focusing on ER receptor or subtype. Our results provide a ranking of published predictors with regard to their applicability on independent data sets. The best discriminative pattern can be reached by including all available samples. When screening relevant publications and entries in public databases, we detected 389 microarray-based data sets that had been repeatedly entered in GEO with new accession numbers. Since the inclusion of repeated microarray data that were not derived independently could result in overoptimistic classification and lack of reproducibility in validation studies, we emphasize the necessity for curating public databases to eliminate such anomalies. Another comparative analysis was based on 374 genes extracted from published gene lists relevant for breast cancer prognosis [20] , but did not validated the original gene sets like our study. The authors included redundant samples from GSE2990 and GSE4990. Although their repeatedly validated gene-set predicted clinical response better than tumor size, lymph node status, ER status and grade, the presence of redundant data might influence their results.
Predictions of clinical outcome based on gene expression patterns were met with some skepticism, because multiple, non-overlapping gene sets were able to predict molecular phenotypes correctly. For example, a recent study on microarray data related to breast cancer, renal tumors and lymphoma and including clinical information compared the prediction errors using different training sets. The results suggested that expression profiles established in this way showed little overlap [21] . We achieved significant prediction success using different gene sets established on different microarray platforms, and therefore we provide additional support to this finding.
To increase the significance of the prediction, we have used all available samples to build the consensus predictor instead of splitting the microarray data into a training and test set. Ntzani et al. found by investigating 84 diverse microarray studies that significant associations were 3.5 times more likely when the sample size was doubled and 9.7 times more likely when the number of microarray probes were increased tenfold [22] . These authors also advocated the use of complete cross validation in order not to inflate the predictive power [22] . Accordingly, we included all samples in the initial training set and the Kaplan-Meier plot was based on the results of a leave-oneout cross validation (LOOCV). The LOOCV provides a nearly unbiased estimate of the true error rate of the classification procedure [23] . At the end of the LOOCV process, we have constructed different models for each sample only to estimate the prediction error. The model that is suggested for future predictions is the one constructed at the beginning using all 1,079 samples.
We used the supervised principal component analysis and the prediction analysis of microarrays for classification. More sophisticated algorithms do not perform better than the simple ones as shown by Dudoit and colleagues who have evaluated simple-diagonal linear discriminant analysis and nearest-neighbour classification-and complex-classification trees and machine-learning techniques such as bagging and boosting-classification methods [24] . The analysis was performed after mapping the gene sets to a single platform. This mapping relies on the proven fundamental assumption that different microarrays are capable to reproducibly measure gene expression [25] .
In our study we demonstrate that different microarray datasets can be used to predict relapse in an independent dataset established using single channel microarrays. In this context, our study is a validation for the original studies using a much larger patient cohort. Finally, we established a database incorporating the genes from 20 microarray studies and gene expression data for 1,079 patients. This BRB Arraytools compatible database in an easily extendable format and can be used to validate future studies or to classify individual patients.
